Exchange Traded Concepts LLC Buys 2,072 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Exchange Traded Concepts LLC increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 20.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,056 shares of the specialty pharmaceutical company’s stock after buying an additional 2,072 shares during the period. Exchange Traded Concepts LLC owned 0.06% of ANI Pharmaceuticals worth $719,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of ANIP. Millennium Management LLC increased its stake in shares of ANI Pharmaceuticals by 1,005.8% during the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares in the last quarter. American Century Companies Inc. increased its stake in shares of ANI Pharmaceuticals by 99.2% during the second quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company’s stock valued at $6,357,000 after purchasing an additional 49,717 shares in the last quarter. Lisanti Capital Growth LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $2,218,000. Hussman Strategic Advisors Inc. bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $2,178,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 3.5% during the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock valued at $40,132,000 after purchasing an additional 21,053 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ANIP. Truist Financial reaffirmed a “hold” rating and set a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Finally, Raymond James increased their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $77.00.

ANI Pharmaceuticals Trading Up 0.3 %

Shares of ANIP stock opened at $60.31 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average is $59.45 and its 200 day moving average is $62.44. The stock has a market capitalization of $1.26 billion, a P/E ratio of 37.69 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company’s revenue was up 18.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.06 EPS. Research analysts expect that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.